3 results
Approved WMOCompleted
The proportion of patients in GC-free remission after 20 weeks.
Approved WMORecruiting
The aim of this study is to investigate non-inferiority of rituximab SC 336 mg to rituximab IV 200 mg.
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.